Milnacipran - Pierre Fabre
Alternative Names: Dalcipran; F 2207; Impulsor; Ixel; JONCIA; Midacipran; Midalcipran; Savella; TN 912; ToledominLatest Information Update: 05 Nov 2023
At a glance
- Originator Pierre Fabre
- Developer AbbVie; Allergan; Asahi Kasei; Pierre Fabre; University of Tennessee
- Class Amides; Amines; Analgesics; Antidepressants; Cyclopropanes; Irritable bowel syndrome therapies; Small molecules
- Mechanism of Action Adrenergic uptake inhibitors; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Fibromyalgia; Major depressive disorder
- Discontinued Vulvodynia
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 01 Jul 2019 Launched for Fibromyalgia in Australia, prior July 2019 (PO)
- 29 Jun 2017 Discontinued - Phase-III for Vulvodynia in USA (PO)